Erlotinib (Tarceva) in the treatment of non-selected population of 1735 patients with advaced non-small-cell lung cancer (NSCLC) from Czech Republic

• Authors: SKŘIČKOVÁ Jana; PEŠEK Miloš; ZATLOUKAL Pavel; KOLEK Vítězslav; SALAJKA František; KOUBKOVÁ Leona; ZEMANOVÁ Milana; SIXTOVÁ Dimka; ROUBEC Jaromír; COUPKOVÁ Helena; TOMÍŠKOVÁ Marcela; HRNČIARIK Michal; GRYGARKOVÁ Yvona; STICHA Michal
• Year of publication: 2011
• Type: Conference abstract
• MU Faculty or unit: Faculty of Medicine
• Description: The human epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) erlotinib (Tarceva) is approved for use in advanced, pretreated NSCLC. This analysis presented examines data obtained from the Czech population of NSCLC pts who received erlotinib.